Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Sartor on Implications of PSMA-PET Positivity in Prostate Cancer

March 31st 2020

A. Oliver Sartor, MD, discusses the implications of prostate-specific membrane antigen-PET positivity in prostate cancer.

Dr. Antonarakis on the Utility of Sipuleucel-T Plus Radium-223 in Nonmetastatic CRPC

March 31st 2020

Emmanuel S. Antonarakis, MBBCh, discusses the utility of sipuleucel-T plus radium-223 in nonmetastatic castration-resistant prostate cancer.

Dr. Agarwal on the Safety of Cabozantinib/Atezolizumab in mCRPC

March 31st 2020

Neeraj Agarwal, MD, discusses the safety profile ofcabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer.

Darolutamide Approved in Europe for Nonmetastatic CRPC

March 30th 2020

The European Commission has approved darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer who are at high risk for developing metastatic disease.

Familial History of Prostate Cancer Strongly Linked With Early-Onset Disease

March 30th 2020

While the risk of prostate cancer varies by family history, it is strongly associated with early onset of disease.

Dr. de Wit on the AEs With Cabazitaxel in the CARD Trial in mCRPC

March 28th 2020

Ronald de Wit, MD, PhD, group leader, Experimental Systematic Therapy of Urogenital Cancers program, Erasmus MC Cancer Institute, Rotterdam, Netherlands, discusses the adverse events (AEs) with cabazitaxel (Jevtana) in the phase III CARD trial in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Hussain on the Implications of the PROfound Trial in mCRPC

March 28th 2020

Maha Hussain, MD, FACP, FASCO, Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine, and Deputy Director at the Robert H. Lurie Comprehensive Cancer Center, of Northwestern University Feinberg School of Medicine, discusses the implications of the phase III PROfound trial in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Parker on the Results of the RADICALS-RT Trial in Prostate Cancer

March 28th 2020

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the results of the phase III RADICALS-RT trial in prostate cancer.

Dr. Tagawa on Remaining Questions With PSMA-Targeted Radionuclide Therapy in mCRPC

March 28th 2020

Scott T. Tagawa, MD, MS, discusses remaining questions regarding treatment selection and PSMA imaging in metastatic castration-resistant prostate cancer.

Dr. Antonarakis on PD-1/PD-L1 Monotherapy in Prostate Cancer

March 28th 2020

Emmanuel S. Antonarakis, MBBCh, discusses the optimal use of PD-1/PD-L1 monotherapy in prostate cancer.

Stereotactic Ablative Radiation Slows Progression in Oligometastatic Prostate Cancer

March 27th 2020

Stereotactic ablative radiation reduced disease progression compared with observation in patients with oligometastatic prostate cancer.

Dr. McKay on Rationale for Real-World Analysis of Radium-223 in mCRPC

March 27th 2020

Rana R. McKay, MD, discusses the rationale for conducting a real-world analysis of radium-223 dichloride in metastatic castration-resistant prostate cancer.

Dr. Freedland on Real-World Evidence Vs PREVAIL Trial in mCRPC

March 27th 2020

Stephen J. Freedland, MD, discusses how real-world evidence with the use of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) compares with data from the phase III PREVAIL trial.

Dr. Gomella on Screening Recommendations in Prostate Cancer

March 27th 2020

Leonard G. Gomella, MD, discusses recommendations for screening in prostate cancer.

Dr. Tagawa on Safety Profile of 225Ac-J591 in mCRPC

March 27th 2020

Scott T. Tagawa, MD, MS, discusses the safety profile of novel monoclonal antibody 225Ac-J591 in metastatic castration-resistant prostate cancer.

Dr. Grivas on the Role of Targeted Therapy in Prostate Cancer

March 27th 2020

Petros Grivas, MD, PhD, discusses the role of targeted therapy in prostate cancer.

Long-Term Follow-Up Validates Noninferiority Between Radiation Regimens in Prostate Cancer

March 25th 2020

Moderate hypofractionated intensity-modulated radiation therapy did not show biochemical and/or clinical disease failure rate superiority compared with conventionally fractioned IMRT for men with intermediate- and high-risk prostate adenocarcinoma.

68Ga-PSMA-11 PET Imaging Poised to Be Useful Management Tool in Biochemically Recurrent Prostate Cancer

March 25th 2020

Wolfgang Fendler, MD, highlights the potential impact 68Ga-PSMA-11 PET imaging may have on the treatment of patients with biochemically recurrent prostate cancer.

Dr. Cone on Evaluating the Relative Cardiac Risk of GnRH Agonists Versus Antagonists in Prostate Cancer

March 23rd 2020

Eugene B. Cone, MD, a urologic oncology fellow at Brigham and Women’s Hospital and Massachusetts General Hospital, discusses the methods that were used to evaluate the relative cardiac risk of gonadotropin-releasing hormone (GnRH) agonists versus antagonists in patients with prostate cancer.

Dr. Graff on the KEYNOTE-641 Trial in mCRPC

March 23rd 2020

Julie N. Graff, MD, associate professor of medicine, Oregon Health & Science University Knight Cancer Institute, discusses the phase III KEYNOTE-641 trial in metastatic castration-resistant prostate cancer (mCRPC).